Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00325351 · ClinicalTrials.gov registry record · Phase 2
ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
A Phase 2 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT00325351 is a Phase 2 study that has completed, run by Bayer. The registered enrollment target is 45 participants.
The verdict
NCT00325351, a Phase 2 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
Interventions
- DRUG Sagopilone (ZK 219477) + carboplatin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2006-08-24 |
| Est. Completion | 2009-03-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00325351
The ClinicalTrials.gov registry entry for NCT00325351 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Sagopilone (ZK 219477) + carboplatin is the first listed.
NCT00325351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00325351 about?
NCT00325351 is a clinical study titled "ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer". The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with carboplatin in patients with recurrent ovarian cancer, who previously have had a good response with cisplatin or carboplatin, is safe and helps to decrease or stop tumor growth.
What is the current status of trial NCT00325351?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2006-08-24. Estimated completion is 2009-03-25.
What interventions are being tested in trial NCT00325351?
The interventions under investigation include: Sagopilone (ZK 219477) + carboplatin (DRUG).
Who is sponsoring clinical trial NCT00325351?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.